Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study.

MLA

Elkayal, Omar, et al. “Dosing of IV Posaconazole to Treat Critically Ill Patients with Invasive Pulmonary Aspergillosis: A Population Pharmacokinetics Modelling and Simulation Study.” The Journal of Antimicrobial Chemotherapy, vol. 79, no. 7, July 2024, pp. 1645–56. EBSCOhost, https://doi.org/10.1093/jac/dkae160.

APA

Elkayal, O., Mertens, B., Wauters, J., Debaveye, Y., Rijnders, B., Verweij, P. E., Brüggemann, R. J., Spriet, I., & Dreesen, E. (2024). Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. The Journal of Antimicrobial Chemotherapy, 79(7), 1645–1656. https://doi.org/10.1093/jac/dkae160

Chicago

Elkayal, Omar, Beatrijs Mertens, Joost Wauters, Yves Debaveye, Bart Rijnders, Paul E Verweij, Roger J Brüggemann, Isabel Spriet, and Erwin Dreesen. 2024. “Dosing of IV Posaconazole to Treat Critically Ill Patients with Invasive Pulmonary Aspergillosis: A Population Pharmacokinetics Modelling and Simulation Study.” The Journal of Antimicrobial Chemotherapy 79 (7): 1645–56. doi:10.1093/jac/dkae160.